Navigation Links
ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
Date:1/24/2008

Changes in prescribing behavior appear inconsistent with ACC statements on

ENHANCE study results

MOUNT LAUREL, N.J., Jan. 24 /PRNewswire/ -- ImpactRx, Inc., the pioneering force in measuring the impact of pharmaceutical promotion on physicians' prescribing behavior, has released data showing a sharp drop in prescribing Zetia and Vytorin since Merck / Schering-Plough's release of the ENHANCE study results on January 14. That study was designed to determine if ezetimibe (Zetia) and simvastatin used in combination was more effective than simvastatin alone in slowing the growth of plaque in the carotid artery. There was no statistically significant difference between treatment groups on the primary endpoint: mean change in the intima-media thickness (IMT) measured at three sites in the carotid arteries.

In the past week, primary care physicians' usage of Vytorin, the combination of Zetia and simvastatin, has declined from 15% of new treatment decisions to 5%. Among cardiologists, the decline has been less severe, from 15% of new treatment decisions to around 8%. Zetia's share of this treatment population has declined from about 8% to less than 5% among both PCPs and cardiologists. Switching from Vytorin and Zetia is driving this trend, along with less initial use among patients naive to drug therapy. As of yesterday, it appears this decline may have begun to stabilize.

"The reaction among physicians and patients is a bit puzzling," said John Kain, Vice President of Marketing at ImpactRx. "The American College of Cardiology released a statement recommending 'that major clinical decisions not be made on the basis of the ENHANCE study alone'. Both medicines were generally well tolerated and the overall incidence rates of cardiac events were nearly identical between both treatment groups, it concluded. The College specifically noted, 'There should be no reason for patients to panic'," Kain continued, "but the data certainly indicate a change in attitude towards these drugs has occurred."

"ImpactRx collects information directly from a panel of high prescribing physicians," noted Kain. "By focusing on physicians' new written prescriptions (NWRx), defined as drug therapy for newly diagnosed patients, add-on therapy or brand switches, our research is more sensitive and typically leads dispensed (NRx) trend changes. Our methodology provides unique insight, especially during periods of rapid change in prescribing behavior driven by market events."

Kain continued, "As always, ImpactRx will be monitoring prescribing changes closely. The incidence of drug switching in this category has risen dramatically since ENHANCE was released, with simvastatin now garnering two- thirds of those changes from Vytorin. Yet patient requests have increased only moderately. We'll be conducting research among physicians to explore their current attitudes towards Zetia and Vytorin and to understand their concerns regarding the latest clinical data."

About ImpactRx

Founded in October 2000, the physician networks of ImpactRx are the source of an unprecedented intelligence capability for tracking the promotional initiatives of the pharmaceutical industry and for measuring their impact on physician prescribing behavior. Based in Mount Laurel, New Jersey, ImpactRx is a private company with investment financing provided by Mediphase Venture Partners (http://www.mediphaseventure.com), Oxford Bioscience Partners (http://www.oxbio.com), Merck Capital Ventures (http://www.merckcapitalventures.com) and 3i Group (http://www.3i.com).

CONTACT:

John Kain

Vice President, Marketing

ImpactRx, Inc.

856-273-0221, ext. 141

jkain@impactrx.com


'/>"/>
SOURCE ImpactRx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor
2. ORTHO EVRA(R) Prescribing Information Updated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., ... , today announced that the company has provided ... University of North Carolina at Chapel Hill and to ... designed to characterize and quantify HIV reservoir and viral ... pharmacological intervention. The HIV Cure Center is a joint ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology:
(Date:8/18/2017)... St. Louis, Missouri (PRWEB) , ... August 18, 2017 , ... ... ” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To ... way they help children learn social and emotional skills, she created the Time-In Toolkit, ...
(Date:8/18/2017)... ... August 18, 2017 , ... With ... specializing in bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner ... of aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , ...
(Date:8/18/2017)... ... 18, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... on false teachings pertaining to the mother of the Savior whom the world calls “Mother ... different picture of the role of this historical woman. , “The world bows, kisses ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that ... its marketing efforts with its product now available through Jet.com. , After 25 ... The effervescent powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced ...
(Date:8/18/2017)... CA & CARMEL, IN (PRWEB) , ... August 18, 2017 , ... ... on its 36th annual list, the most prestigious ranking of the nation's fastest-growing private ... been included in the exclusive Inc. 5000 ranking . This year’s ranking reflects ...
Breaking Medicine News(10 mins):